



Correction to: Human Papillomavirus and Factors Associated with Recurrence in Sinonasal Inverted Papillomas from Poland and Spain

M. Fulla^{1,2} · T. Szafarowski³ · J. Frias-Gomez^{4,5} · B. Quiros^{4,5,6} · O. Clavero^{4,5,6} · M. Gomà^{2,7} · M. A. Pavon^{4,5,6} · O. Jurek-Matusiak³ · H. R. Lares^{1,2} · M. Maños^{1,2,8} · L. Alemany^{4,5,9} · M. Mena^{4,5,6} · X. Gonzalez^{1,2}

Published online: 10 February 2020
© Springer Science+Business Media, LLC, part of Springer Nature 2020

Correction to: Head and Neck Pathology
<https://doi.org/10.1007/s12105-019-01125-y>

The original version of this article unfortunately contained a mistake. Three values in Table 1 were incorrect. In “months of recurrence”, range row, the intervals should be in numbers. They should read as 3–83 instead of Mar-83, 9–83 instead of Sep-83 and 3–36 instead of Mar-36. The corrected Table 1 is given below. The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s12105-019-01125-y>.

✉ M. Fulla
mfulla@bellvitgehospital.cat

¹ Department of Otorhinolaryngology, Hospital Universitari Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

² Program of Molecular Mechanisms and Experimental Therapy in Oncology, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet de Llobregat, Barcelona, Spain

³ Department of Otorhinolaryngology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Warsaw, Poland

⁴ Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO) – L’Hospitalet de Llobregat, Barcelona, Spain

⁵ Epidemiology, Public Health, Cancer Prevention and Palliative Care Program, IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain

⁶ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III, Madrid, Spain

⁷ Department of Pathology, Hospital Universitari Bellvitge, L’Hospitalet de Llobregat, Barcelona, Spain

⁸ University of Barcelona, Barcelona, Spain

⁹ Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain

Table 1 Demographic and clinical characteristics of SNIP patients included in the study

Characteristics	Total SNIPs (n = 79) No. (%) ^a	Spanish SNIPs (n = 46) No. (%)	Polish SNIPs (n = 33) No. (%)	p-value ^a
Age at diagnosis				0.460
Mean (SD)	56.2 (16.1)	55.0 (15.0)	57.8 (17.7)	
Range	19–91	19–85	23–91	
Gender				0.150
Male	53 (67.1)	34 (73.9)	19 (57.6)	
Female	26 (32.9)	12 (26.1)	14 (42.4)	
Period of diagnosis				<0.001
1995–2000	7 (8.9)	7 (15.2)	0 (0.0)	
2001–2006	17 (21.5)	17 (37.0)	0 (0.0)	
2007–2012	24 (30.4)	22 (47.8)	2 (6.1)	
2013–2017	31 (39.2)	0 (0.0)	31 (93.9)	
Tobacco use				0.010
Never smoker	33 (41.8)	13 (28.3)	20 (60.6)	
Ever smoker	44 (55.7)	31 (67.4)	13 (39.4)	
Missing	2 (2.5)	2 (4.3)	0 (0.0)	
Alcohol use				0.616
Never drinker	56 (70.9)	33 (71.7)	23 (69.7)	
Ever drinker	21 (26.6)	11 (23.9)	10 (30.3)	
Missing	2 (2.5)	2 (4.3)	0 (0.0)	
Previous history of HPV-related pathology				1.000
Yes	3 (3.8)	2 (4.3)	1 (3.0)	
No	74 (93.7)	42 (91.3)	32 (97.0)	
Missing	2 (2.5)	2 (4.3)	0 (0.0)	
Krouse classification				<0.001
1	33 (41.8)	28 (60.9)	5 (15.2)	
2	23 (29.1)	11 (23.9)	12 (36.4)	
3	16 (20.3)	3 (6.5)	13 (39.4)	
4	4 (5.1)	1 (2.2)	3 (9.1)	
Missing	3 (3.8)	3 (6.5)	0 (0.0)	
Transitionalepithelium				0.015
Absence	19 (24.1)	16 (34.8)	3 (9.1)	
Presence	60 (75.9)	30 (65.2)	30 (90.9)	
Squamousepithelium				0.001
Absence	45 (57.0)	19 (41.3)	26 (78.8)	
Presence	34 (43.0)	27 (58.7)	7 (21.2)	
Columnarepithelium				0.316
Absence	23 (29.1)	11 (23.9)	12 (36.4)	
Presence	56 (70.9)	35 (76.1)	21 (63.6)	
Hyper-parakeratosis				1
Absence	76 (96.2)	44 (95.7)	32 (97.0)	
Presence	3 (3.8)	2 (4.3)	1 (3.0)	
Papillar or exophytic lesion adjacent to SNIP				<0.001
Absence	61 (77.2)	44 (95.7)	17 (51.5)	
Presence	18 (22.8)	2 (4.3)	16 (48.5)	

Table 1 (continued)

Characteristics	Total SNIPs (n = 79) No. (%) ^a	Spanish SNIPs (n = 46) No. (%)	Polish SNIPs (n = 33) No. (%)	p-value ^a
Polymorphonuclear neutrophil inflammatory intralesional infiltrate				1.000
Absence	2 (2.5)	1 (2.2)	1 (3.0)	
Presence	77 (97.5)	45 (97.8)	32 (97.0)	
Polymorphonuclear neutrophil inflammatory perilesional infiltrate				0.418
Absence	1 (1.3)	0 (0.0)	1 (3.0)	
Presence	78 (98.7)	46 (100.0)	32 (97.0)	
Recurrence				0.268
No	59 (74.7)	31 (67.4)	28 (84.8)	
Yes	17 (21.5)	12 (26.1)	5 (15.2)	
Missing	3 (3.8)	3 (6.5)	0 (0.0)	
Months of follow up				0.003 ^b
Median	52.83	76.63	39.1	
Range	0.23–174.33	0.23–174.33	6.27–66.47	
Months to recurrence				0.469 ^b
Median	14	17	4	
Range	3–83	9–83	3–36	
Progression to invasive cancer				0.502
No	74 (93.7)	41 (89.1)	33 (100.0)	
Yes	2 (2.5)	2 (4.3)	0 (0.0)	
Missing	3 (3.8)	3 (6.5)	0 (0.0)	
HPV positivity				1.000
No	75 (94.9)	44 (95.7)	31 (93.9)	
Yes	4 (5.1)	2 (4.3)	2 (6.1)	

Statistically significant *p* values given in bold

SNIP Sinonasal Inverted Papilloma, SD standard deviation

^aFischer exact test with the exception of age and months to recurrence. where t-student test has been used to compare the median values between populations

^bqreg (quantilte regression): test for equality of medians, equivalent for t-test for medians

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.